Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Core Viewpoint - The FDA has accepted the supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, with a PDUFA goal date set for October 17, 2026, indicating a significant step towards expanding treatment options for this widespread age-related condition [1][2][3]. Company Overview - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [11]. - The company is also advancing phentolamine ophthalmic solution 0.75%, which is currently approved for pharmacologically-induced mydriasis, and is exploring its potential for treating presbyopia and low-light visual disturbances following keratorefractive surgery [11]. Product Details - Phentolamine ophthalmic solution 0.75% is designed to improve near vision while preserving distance vision, with effects lasting up to 20 hours [3]. - The solution is a preservative-free, topical formulation that modulates pupil dynamics through a sympatholytic mechanism, avoiding engagement of the ciliary muscle [3][10]. - The sNDA is supported by positive results from pivotal Phase 3 clinical trials (VEGA-2 and VEGA-3), which met primary and key secondary endpoints without serious adverse events [4]. Market Potential - Presbyopia affects approximately 90% of adults in the U.S. over the age of 45, indicating a large potential market for phentolamine ophthalmic solution if approved [2]. - The company has a global licensing agreement with Viatris, granting exclusive rights to commercialize phentolamine ophthalmic solution 0.75% in the U.S. [6]. Upcoming Events - Data from the VEGA-3 trial is expected to be presented at the American Society of Cataract and Refractive Surgery (ASCRS) meeting in April 2026 and the Association for Research in Vision and Ophthalmology (ARVO) meeting in May 2026 [4].